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The non-lactating female breast is subject to cyclic exposure of the
ovarian hormones oestradiol and progesterone. In fact, breast
tissue is highly responsive to changes in sex hormone concentra-
tions and discrete histological stages can readily be identified
throughout each menstrual cycle by expert breast pathologists
(Vogel et al, 1981). Breast cancer cells frequently maintain
hormone dependency, which was recognized at the end of the last
century based upon the observation that metastatic breast cancer
may remit after extirpation of the premenopausal woman’s ovaries
(Beatson, 1896). In today’s clinical management of breast cancer,
endocrine therapies, especially strategies antagonizing the action
of oestradiol, are established adjuvant and palliative treatment
options. In breast cancer, as well as in many other cancers, angio-
genesis was identified as a crucial process for growth and metas-
tasis since tumours must actively recruit blood supply in order to
be able to grow beyond a size of 1–2 mm3 (Gimbrone et al, 1972).
Furthermore, evidence seen in animal models and humans link the
onset of growth of dormant micrometastases to their acquisition
of angiogenic activity (Hanahan and Folkman, 1996). Therefore,
elucidating the mechanisms of angiogenesis is of enormous
clinical importance to understand the mechanisms of disease
progression, and to design preventive strategies. One of the most
important and specific mediators of angiogenesis identified so far
is vascular endothelial growth factor (VEGF). The initially charac-
terized molecule is now termed VEGF-A and belongs to a family
of structurally related peptides (VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PIGF). Different isoforms of VEGF-A arise by alterna-
tive splicing of mRNA and are named by the number of amino
acids in the monomeric protein (VEGF189, VEGF165, VEGF121)
(reviewed by Ferrara and Davis-Smyth, 1997). VEGF-A is
strongly expressed in many human breast cancers and expression
levels are closely correlated with microvessel density in angio-
genic ‘hot spots’ (Toi et al, 1995). Cytosolic levels of VEGF in
breast cancer tissue was identified as a prognostic marker in node-
negative breast cancer patients with respect to relapse free and
overall survival (Gasparini et al, 1997). Up to now, very little is
known about the hormonal dependency of microvascular changes
in normal breast and breast cancer. To some extent, angiogenesis
in the human breast has been assessed functionally by Doppler
sonography and magnetic resonance imaging (MRI). So far, these
studies indicate a possible influence of the ovarian hormones on
the vasculature. The assessment of tissue vascularization by
Doppler sonographic measurements of vascular resistance and
blood flow velocities suggests differences in vascular patterns
between premenopausal and post-menopausal patients, and
between tumour and normal breast tissue (Villena-Heinsen et al,
1998). Furthermore, parenchymal contrast enhancement patterns
in MRI, which are thought to be caused by increased vessel
density and permeability (Buadu et al, 1996), are changing
depending on the stage of the patients’ menstrual cycle (Müller-
Schimpfle et al, 1997). Based upon these observations we
hypothesized that the regulation of microvascular functions and
angiogenesis in breast tissue, a well known target of ovarian
steroid action, is likewise dependent on the hormonal milieu.
VEGF-A, which has been demonstrated as a crucially important
regulator of angiogenesis, seems to be a prime candidate to
mediate hormonally induced changes on blood vessels in the
breast. Preliminary evidence from studies in vitro suggests that
oestrogens and progestins regulate the expression of VEGF in
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.certain breast cancer cells (Nakamura et al, 1996; Hyder et al,
1998). Here, we report, to our knowledge for the first time, that in
vivo VEGF-A-expression levels in non-neoplastic breast tissue
decrease after menopause.
MATERIALS AND METHODS
Human breast tissue samples
Paired malignant and adjacent non-neoplastic breast tissue
samples from 19 unselected women with primary breast cancer
were included in the study. The study was approved by the institu-
tional review board. The endocrine status was determined based
upon menstrual history, history of previous steroid hormone treat-
ments and determination of plasma levels of FSH, oestradiol and
progesterone on the day before surgery. Postmenopausal status
was defined by one of the following:
• no spontaneous menses for at least 1 year in women older
than 55
• plasma FSH levels higher than 40 IU l–1
• plasma oestradiol levels below 15 pg ml–1.
Histology, grading, tumour size, node status and oestrogen- and
progesterone receptor status are summarized in Table 1. Breast
tissue containing the palpable tumour was put on ice immediately
upon removal and a representative sample of approximately
5  ´ 5 ´ 5 mm was taken from the tumour, and from the macro-
scopically tumour-free margin of the surgical specimen at a
distance of at least 2 cm. The paired samples were snap-frozen in
liquid nitrogen within 15 min upon removal of the tissue and
stored in a freezer at – 80°C for no longer than 6 months until
mRNA-isolation.
RNA-isolation
PolyA  +RNA (mRNA) was purified after binding to biotin-labelled
oligo(dt)20 by extraction with streptavidin-coated magnetic beads
using a commercially available kit (Boehringer, Mannheim,
Germany), following the procedures outlined by the manufacturer.
DNAse-treated samples were stored at –80°C.
Quantitative RT-PCR-assay
Reverse transcription polymerase chain reaction (RT-PCR) kits
were purchased from Perkin-Elmer (Überlingen, Germany).
cDNAs were synthesized from 25–50 ng mRNA using random
hexamer primers. cDNA synthesis was carried out as suggested by
the kit protocol, except that the RNA was denatured at 70°C for
5 min before RT for 45 min at 42°C. After an incubation at 99°C
for 5 min to inactivate the reverse transcriptase, 10 ml cDNA
aliquots were used in subsequent PCR reactions. Primers for
VEGF-A and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were designed based upon published human cDNA
sequences sequences with NBI-Oligo primer analysis software
(MedProbe, Oslo, Norway). Both sets of primers cross intron
sequences of the respective genes allowing to control for contami-
nating genomic DNA which would be detected by amplification of
additional larger bands. Negative controls without mRNA were
also performed. Custom synthesized VEGF-A primers (forward:
5¢-CTGCTGTCTTGGGTGCATTGG-3¢, reverse: 5¢-CACCGC-
CTCGGCTTGTCACAT-3¢) and GAPDH primers (forward: 5¢-
GGCACCGTCAAGGCTGAGA-3¢, reverse: 5¢-AGCAGAGGG-
GGCAGAGATGAT-3¢) were obtained from Biometra (Göttingen,
Germany). Quantitative PCR for VEGF-A was carried out using
GAPDH as an internal standard in the same tube similar as
described previously (Greb et al, 1997). Briefly, 10 ml of cDNA
were preamplified for 7 cycles (94°C 45 s, 72°C 120 s) with
VEGF-A-primers by adding 70 ml mastermix (1.88 mM magne-
sium chloride, 50 mM potassium chloride, 10 mM Tris–HCl
pH 8.3, 1.5 U AmpliTaq DNA Polymerase, 0.25 mg Taq Start
Antibody, Clontech, Heidelberg, Germany, 1.125 mM VEGF-A-
primer). In preliminary experiments the preamplification of
cDNAs with VEGF-A primers for 7 cycles before adding GAPDH
primers was found to result in equal amplification efficiencies of
GAPDH and VEGF-A-isoforms in the range PCR products were
detectable by polyacrylamide gel electrophoresis. Subsequently,
10 ml mastermix containing GAPDH-primers (1.125 mM) were
added and amplification continued (94°C 45 s, 65°C 45 s, 72°C
134 s + 2 s extension per cycle) until aliquots of the reaction were
removed every 3 cycles for kinetic analysis. The range of PCR-
cycles, in which parallel amplification occurred for VEGF-A and
GAPDH PCR-products, was determined for each cDNA sample in
preliminary experiments. In subsequent experiments 20 ml aliquots
of PCR-products were removed starting between 14 and 26 cycles
after adding GAPDH-primer depending on the optimal amplifica-
tion range of the sample. At least four aliquots were removed
every 3 cycles for later kinetic analysis in all samples. PCR-prod-
ucts were subjected to 5% polyacrylamide gel electrophoreses and
the intensity of ethidium bromide-stained bands was determined
from Polaroid photographs by the Lumi-Imager Analysis System
(Boehringer, Mannheim, Germany). In all samples, a kinetic
analysis was performed by plotting the signal intensity of PCR-
products against the number of PCR-cycles (Figure 1). Relative
VEGF-A gene expression levels was expressed for each VEGF
mRNA isoform as the ratio between the arbitrary signal intensity
of the respective VEGF-A-PCR product divided by the signal
intensity of the GAPDH-derived PCR product in the range where
parallel amplification could be demonstrated in the kinetic analysis
plot. The intra- and interassay coefficients of variation were 9%
and 22% respectively.
Southern hybridization
The identity of PCR-products was confirmed by Southern
hybridization employing 30-mer oligonucleotide probes specific
to the VEGF-A (located in exon 3 and exon 7 respec-
tively,5¢-GCCATCCTGTGTGCCCCTGATGCGATGCGG-3¢, 5¢
CCTGTG-GGCCTTGCTCAGAGCGGAGAAAGC-3¢ TIB Mol-
Biol, Berlin, Germany) and GAPDH cDNA sequences
(5¢-CCACCATGGAGAAGGCTGGGGCTCATTTGC-
3¢¼TGGGC¼ Biometra, Göttingen, Germany) internal to the
PCR-primers as described previously (Greb et al, 1997). The exon
3-specific probe is expected to hybridize with all VEGF-A
isoforms, the exon 7-specific probe is expected to hybridize only
with VEGF 189 and VEGF 165.
Statistics
The data were analysed by the two-way-ANOVA, Student’s t-test
and regression analysis. Bars indicate mean ± standard error.
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RT-PCR was used to determine the relative expression levels of
VEGF-A mRNAs coding for the isoforms VEGF189, VEGF165
and VEGF121, referenced to GAPDH expression in breast cancer
lesions and the surrounding non-neoplastic tissue depending on
the hormonal exposure in vivo (Figure 1). Clinical data and
expression levels are summarized in Table 1. As shown in Figure
2, only in non-neoplastic tissue was VEGF-A expression depen-
dent on the patient’s menopausal status. In normal breast tissue,
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Figure 1 A representative sample showing kinetic analysis of RT-PCR products. (A) After preamplification of cDNA with VEGF-A primers for seven PCR-
cycles, GAPDH primers were added to the reaction. Aliquots of PCR products were removed from the reaction after 17, 20, 23 and 26 cycles and subjected to
polyacrylamide gel electrophoresis. The intensity of the bands was determined from digitized images of polaroid photographs using the Lumi-Imager Analysis
system in arbitrary Boehringer Light Units (BLU). (B) In all samples the ratio between VEGF-A isoforms and GAPDH was calculated from BLUs during the
phase of parallel, exponential amplification. In this case the means of values obtained at 20/27 and at 23/30 cycles were used
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Figure 2 Relative expression levels of VEGF-A isoforms. In non-neoplastic (A) breast tissue VEGF-A isoform expression was significantly higher in
premenopausal women compared to post-menopausal women (means ± s.e.m.). No difference was found in tissues from cancer lesions (B)
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Figure 3 Correlation of VEGF-A expression with age. In non-neoplastic tissue (A), patient age and VEGF-A-expression (sum of VEGF-A isoforms) were
inversely correlated. No significant correlation could be demonstrated in cancerous tissue (B). In postmenopausal women, only one 81-year-old patient had
received oestrogen replacement therapy for several years prior to surgery (black square (n), data point shown but not included in data analysis)the expression of all detected VEGF-A isoforms was significantly
higher in premenopausal compared to post-menopausal women
(P = 0.02). In contrast, VEGF-A expression levels in cancer
lesions were similar between the two groups of patients.
Consequently, in those patients not having received hormone
replacement therapy prior to breast surgery, VEGF-A expression
and age were inversely correlated in non-neoplastic breast tissue
(P < 0.006), but not in cancer lesions (Figure 3), indicating that an
age-dependent decrease of steroidal exposure of the tissue might
influence VEGF-A expression in breast tissue. The relative ratio of
VEGF-A isoforms to each other was similar between benign
(189/165/121 = 11%/34%/55%) and malignant (189/165/121 =
12%/36%/53%) tissues. Other clinical parameters, such as tumour
size, presence or absence of lymph node metastases and oestrogen
receptor/progesterone receptor-status were not significantly asso-
ciated with VEGF-A expression levels in cancer lesions (Table 1).
PCR-product identity could be verified by sequence specific
probe hybridization (Southern hybridization). Sequential probing
with three specific oligonucleotides recognizing sequences situ-
ated in exon 3 and exon 7 of the human VEGF gene and a
sequence of the human GAPDH gene respectively, gave the
expected signal patterns. The GAPDH-specific probe resulted in a
band at the position of the corresponding PCR product at 187 base
pairs (bps), VEGF–exon 7-specific probe gave two bands at the
location of VEGF189- and VEGF165-derived PCR products at
638 and 566 bps and VEGF–exon 3-specific probe gave three
bands at the location of VEGF189-, VEGF165- and VEGF121-
derived PCR products (638, 566 and 434 bps) (data not shown).
DISCUSSION
To our knowledge, this is the first report that in normal breast
tissue in vivo VEGF-mRNA expression levels decrease age-
dependently, suggesting that the ovarian steroids might be
involved in the regulation of this key angiogenic factor. However,
differences in VEGF-A expression levels between pre- and post-
menopausal patients are only detectable in normal breast tissue
and not in the cancerous lesion itself. Based upon our data, the
hormonal dependency of VEGF-A expression seems to disappear
in the majority of cancerous cells in breast tumours which would
be compatible with our understanding that onset and development
of cancer appears to involve tumour desensitization to host regula-
tory signals (Dickson, 1992).
Interestingly, these preliminary findings are in line with
previous studies assessing angiogenesis in breast tissue indirectly
by perfusion measurements in vivo. Villena-Heinsen et al (1998)
reported a significant correlation between Doppler sonographi-
cally measured vascular resistance indices and age in normal
breast tissue of post-menopausal women. This phenomenon could
not be demonstrated in premenopausal women or in tumour
lesions. The influence of the ovarian hormones on vascular func-
tions in the breast is also supported by MRI data of the human
breast. Müller-Schimpfle et al (1997) reported parenchymal
contrast enhancement patterns which fluctuated depending on the
patients’ age and stage of the menstrual cycle. The lowest
enhancement was found in women younger than 35 and older than
50 years, and if the examination was performed between cycle
days 7–20 compared to cycle days 21–26. The results of our study
substantiate previous reports which failed to show an influence of
menopausal status or age on cytosolic levels of VEGF-protein in
breast cancer lesions (Gasparini et al, 1997). Also, the constant
ratio of VEGF-A isoforms relative to each other (VEGF121 >
VEGF 165 > VEGF 189) as observed by us in vivo, seems to
reflect parallel changes of all isoforms, e.g. under different culture
conditions of breast cancer cell lines. The highly soluble protein
VEGF121 which is diffusable into the surrounding tissue seems to
be the predominant isoform in breast cells (Scott et al, 1998a).
Total GAPDH-normalized VEGF-A mRNA expression in
cancer lesions compared to the surrounding tissue appeared to be
up-regulated only in post-menopausal patients in our study. The
absence of VEGF-A up-regulation in breast carcinomas compared
to matched normal breast tissue in our series of premenopausal
patients seems to be contradictory to the dramatic up-regulation of
VEGF in carcinomas compared to their non-neoplstic counterparts
as described by others (Brown et al, 1995; Anan et al, 1996;
Yoshiji et al, 1996; Obermair et al, 1997; Scott et al, 1998b). A
possible explanation for the discrepancy of our data with other
studies might be the use of GAPDH as a reference gene in the
quantitative RT-PCR assay. GAPDH was demonstrated as one of
several genes which are up-regulated in breast ductal carcinoma
compared to histologically normal tissue (Bini et al, 1997) and a
significant correlation of VEGF mRNA and GAPDH mRNA
expression was found in breast carcinomas (Scott et al, 1998b),
possibly because both genes are regulated by hypoxia (Graven
et al, 1998). Potentially, an increased number of VEGF mRNA
transcripts parallel to an up-regulation of GAPDH in carcinoma-
tous tissue might have caused the similar VEGF/GAPDH ratios in
malignant and benign breast tissue allowing only separate compar-
isons in our study for benign and malignant tissue (Figure 2). For
this reason no conclusions can be drawn comparing benign and
malignant tissue to each other. An up-regulation of VEGF expres-
sion in breast carcinomas compared to normal breast tissue using
b-actin as a reference gene was demonstrated by Northern blotting
(Yoshiji et al, 1996) and RT-PCR detectability (Anan et al, 1996).
Similar to our results, Scott et al (1998b) measured insignificantly
higher VEGF mRNA expression levels in the tumour compared to
the surrounding normal tissue by ribonuclease protection assay
using an external spiked control. The range of VEGF expression
between these two groups overlapped to some extend. Subjective
evaluation of tissue sections by in situ hybridization suggested
stronger staining in malignant breast epithelial cells (Brown et al,
1995), but a significant amount of signal for VEGF mRNA could
also be observed in normal breast epithelial cells (Scott et al,
1998b). Taking these studies together, there is strong evidence that
VEGF mRNA expression is indeed up-regulated in breast cancer
tissue compared to normal breast which fits to measurements of
VEGF protein production in breast cancer lesions and matched
control samples (Obermair et al, 1997). Despite possible difficul-
ties in comparing relative VEGF mRNA expression levels
between malignant and benign tissues our findings in each type of
tissue with respect to age and hormone dependency appear never-
theless to be valid because GAPDH gene expression is unlikely
influenced by the hormonal milieu. GAPDH mRNA has been
shown to be broadly expressed across breast tissue sections
(Wright et al, 1997) and not to be regulated by hormonal steroids
in breast cells (Le-Bihan et al, 1998) and human tumour xenografts
(Wright et al, 1995). The validity of the quantitative measurements
was carefully monitored in our study by controlling for amplifica-
tion efficiencies of different RT-PCR products in all samples. 
The dependency of VEGF-A mRNA expression in the breast
from the endocrine milieu, as suggested by our study, extends
previous findings addressing the regulation of VEGF-A in breast
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mRNA expression in several breast cancer cell lines (Scott et al,
1998a) and in normal mammary stromal cells (Hlatky et al, 1994)
in agreement with the VEGF-mediated neovascularization of
hypoxic areas near necrotic regions in human breast tumours
(Wright et al, 1997).
Additionally, tumour angiogenesis, e.g. via up-regulation of
VEGF expression, is thought to be the consequence of a multistep
process caused by a sequence of genetic alterations in tumour
cells. Mutations of the tumour suppressor gene p53 and over-
expression of oncogenes like v-Src and ras were reported to be
associated with increased expression of VEGF (Mukhopadhyay
et al, 1995; Rak et al, 1996). Based upon our results, and the few
reports on hormonal regulation of VEGF in breast cancer it cannot
be ruled out that oestrogens and progestins may stimulate VEGF
production in some breast cancer cells. Hyder et al (1998) demon-
strated a progesterone-dependent up-regulation of VEGF in pro-
gesterone receptor-rich T47-D breast cancer cells but not in all
other cell lines tested. This is in agreement with the observations
of Scott et al (1998a) who failed to detect an effect of female
reproductive hormones on VEGF mRNA expression in several
breast cancer cell lines which did not include T47-D cells. In vivo,
a hormonal dependency of VEGF could be demonstrated so far
only in rat mammary tumours in which VEGF expression was
shown to be stimulated by oestradiol (Nakamura et al, 1996).
In summary, the data of the present study support our hypothesis
that the VEGF-mediated regulation of microvascular functions
and angiogenesis in breast tissue is subject to ovarian steroid
action. Since VEGF-A has emerged as an important prognostic
parameter which closely correlates with microvascular density in
breast cancer (Toi et al, 1995), our study raises several questions
concerning the consequences of hormonal modulation of angio-
genesis in the human breast. While the effects of endocrine treat-
ments like anti-oestrogens and progestins on cell proliferation and
tumour growth were studied extensively, we at present do not
know how the angiogenic potential in breast cancer, in the
surrounding tissue and in distant micrometastases is influenced by
these treatments. Whether or not beneficial effects of endocrine
therapies on growth are supported or counteracted by modulation
of angiogenesis remains to be determined. Also, it is not yet clear
whether the regulation of a key angiogenic factor by ovarian
hormones in normal breast tissue plays a role in the aetiology of
the disease and whether exogenously administered hormones like
oral contraceptives and hormone replacement therapies are able to
contribute to biologically relevant changes in the breast. The small
group of patients investigated so far does not allow to test for a
menstrual cycle-dependent effect on VEGF-A expression.
However, those data might influence the controversially discussed
issue of timing of breast cancer surgery during the menstrual cycle
(Hagen and Hrushesky, 1998) and VEGF secretion of the breast
could contribute to menstrual cycle-dependent changes in serum
levels of VEGF (Benoy et al, 1998; Chung et al, 1998; Heer et al,
1998). Since MRI of the breast seems to be especially susceptible
for VEGF-induced changes in microvascular functions like vessel
permeability, as could be shown by anti-VEGF treatment in nude
mice (Pham et al, 1998), it seems reasonable to expect that the
hormonal exposure of the breast influences parenchymal contrast
enhancement patterns. This may explain why these patterns are
changing depending on the stage of the patients’ menstrual cycle
(Müller-Schimpfle et al, 1997).
In conclusion, our observation that VEGF-A mRNA-expression
levels in normal breast tissue are higher in premenopausal than
post-menopausal breast cancer patients raises further questions
about the effects of endogenous and therapeutic hormonal steroids
on the angiogenic phenotype of the human breast and its effects on
breast cancer.
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